Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats

Journal of Trauma and Acute Care Surgery

Volumn 72, Issue 1, 2012, Pages 177-182

  Iba, Toshiaki ^a   Okamoto, Kohei ^a   Ohike, Tsubasa ^a   Tajirika, Toshihiro ^a   Aihara, Koichiro ^a   Watanabe, Shin ^a   Kayhanian, Hamzeh ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Enoxaparin; Factor Xa inhibitor; Fondaparinux; Low molecular weight heparin; Thromboembolism

Indexed keywords

ENOXAPARIN; FONDAPARINUX; LIPOPOLYSACCHARIDE; PLACEBO; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL EXAMINATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE INCREASE; ENDOTHELIUM INJURY; ENDOTOXEMIA; LEUKOCYTE ADHERENCE; MALE; MICROSCOPY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; WISTAR RAT; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; LEUKOCYTE;

ANIMALS; ANTICOAGULANTS; ENDOTHELIUM, VASCULAR; ENDOTOXEMIA; ENOXAPARIN; FACTOR XA; HEMORRHAGE; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; POLYSACCHARIDES; RATS; RATS, WISTAR;

EID: 84859641340     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31821a83f0     Document Type: Conference Paper

References (25)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
2. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150.
4. Opal SM, Esmon C. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.
5. Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care. 2008;12:R86-R91.
6. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of anti-inflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med. 2003;31: 1108-1112.
7. Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-490.
8. Iba T, Takayama T. Enoxaparin attenuates endothelial damage with less bleeding compared to unfractionated heparin in endotoxemic rats. Shock. 2009;32:530-534.
9. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
10. Sherman DG, Albers GW, Bladin C, et al. PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007;369:1347-1355.
11. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
12. Iba T, Kidokoro A, Fukunaga M, et al. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat. Shock. 2002;17:159-162.
13. Katagiri H, Itoh S, Uchida T, Kawai Y, Watanabe K. Monitoring of plasma concentration of low molecular weight heparin-comparative evaluation with chromogenic and clotting assays. Rinsho Byori. 1999; 47:1046-1051.
14. Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M. Antithrombin modulates the leukocyte-endothelial cell interaction in the staphylococcal enterotoxin B-challenged mouse. J Trauma. 2003;55:546-550.
15. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost. 1995;74: 1474-1477.
16. Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
17. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
18. Kinasewitz GT, Yan SB, Basson B, et al. PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microorganism. Crit Care. 2004;8:R82-R90.
19. Opal SM. Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care. 2001;7:347-353.
20. Levi M, Toh CH, Thachil J, Watson HG. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145:24-33.
21. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci. 2010;67:499-511.
22. van Gils JM, da Costa Martins PA, Mol A, Hordijk PL, Zwaginga JJ. Transendothelial migration drives dissociation of plateletmonocyte complexes. Thromb Haemost. 2008;100:271-279.
23. Matthay MA. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001;344:759-762.
24. Imberti D, Legnani C, Baldini E, et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thromb Res. 2009;124:667-671.
25. Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med. 2006;130:1605-1611.